Shares of Radius Health Inc. (NASDAQ:RDUS) traded down 1.2% during mid-day trading on Tuesday . The stock traded as low as $56.52 and last traded at $56.76, with a volume of 424,954 shares traded. The stock had previously closed at $57.44.

Several analysts have recently issued reports on the company. Jefferies Group increased their target price on Radius Health from $37.00 to $46.00 and gave the stock a “hold” rating in a report on Monday, August 15th. Zacks Investment Research lowered Radius Health from a “hold” rating to a “sell” rating in a report on Monday, August 8th. JPMorgan Chase & Co. reissued a “buy” rating and set a $70.00 target price on shares of Radius Health in a report on Friday, August 5th. Cowen and Company reissued a “buy” rating on shares of Radius Health in a report on Thursday, August 4th. Finally, Maxim Group lowered Radius Health from a “hold” rating to a “sell” rating and set a $24.00 target price on the stock. in a report on Thursday, August 4th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Radius Health presently has an average rating of “Buy” and an average price target of $61.73.

The stock’s market capitalization is $2.44 billion. The company’s 50-day moving average is $47.69 and its 200-day moving average is $37.45.

Radius Health (NASDAQ:RDUS) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.95) by $0.06. During the same quarter in the previous year, the company posted ($0.61) earnings per share. Analysts anticipate that Radius Health Inc. will post ($3.95) EPS for the current fiscal year.

An institutional investor recently bought a new position in Radius Health stock. Dimensional Fund Advisors LP bought a new stake in shares of Radius Health Inc. (NASDAQ:RDUS) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 22,126 shares of the biopharmaceutical company’s stock, valued at approximately $1,362,000. Dimensional Fund Advisors LP owned about 0.05% of Radius Health as of its most recent filing with the SEC.

Radius Health, Inc is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, oncology and endocrine diseases. The Company’s lead product candidate is the investigational drug abaloparatide for subcutaneous injection (abaloparatide-SC), which has completed Phase III development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.